MELI vs MRK: Which Is the Better Buy?
Side-by-side comparison of MercadoLibre, Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-20.
MercadoLibre, Inc. · Consumer Cyclical
$1,632.52
+45.0% upside to fair value
Grade B
High Quality
VS
Merck & Co., Inc. · Healthcare
$114.27
+3.3% upside to fair value
Grade C
High Quality
QuantHub Verdict
MELI has more upside to fair value
(+45.0%).
MRK trades at a lower forward P/E
(22.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MELI |
MRK |
| Current Price |
$1,632.52 |
$114.27 |
| Fair Value Estimate |
$2,367.15 |
$118.00 |
| Upside to Fair Value |
+45.0%
|
+3.3%
|
| Market Cap |
$82.8B |
$282.2B |
| Forward P/E |
43.1x
|
22.4x
|
| EV / EBITDA |
22.5x
|
13.5x
|
| Price / Sales |
2.7x
|
4.3x
|
| Price / FCF |
7.2x
|
20.2x
|
| Revenue Growth YoY |
+30.0%
|
+5.0%
|
| Gross Margin |
45.5%
|
81.9%
|
| Operating Margin |
9.9%
|
27.5%
|
| Return on Equity |
29.6%
|
5.6%
|
| Dividend Yield |
0% |
2.91% |
| FCF Yield |
13.89%
|
4.95%
|
| Analyst Consensus |
Strong Buy
|
Overweight
|
Investment Thesis
MercadoLibre, Inc. operates a leading e-commerce and fintech platform in Latin America, combining a dominant commerce marketplace with a rapidly growing fintech segment. The company benefits from a durable competitive moat driven by network effects, strong brand recognition, and a comprehensive logistics infrastructure. Despite a recent earnings growth decline of 15.6% in the most recent quarter,…
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition an…
Accumulation Zones
| Metric |
MELI |
MRK |
| Zone Low |
$1,775.36 |
$88.50 |
| Zone High |
$2,012.08 |
$100.30 |
| In Buy Zone? |
Yes
|
No
|